Recent Advancements In Neurodegenerative Biomarkers: Progress Towards A Diagnostic Blood Test For Alzheimer’s Disease

April 23, 2021

Kevin Hrusovsky - Quanterix Chairman, Chief Executive Officer, President
Charlotte Teunissen, PhD - UMC Amsterdam
Henrik Zetterberg, PhD - University of Gothenberg

Please complete the form to access the video.

By submitting this form, you agree to Quanterix’s Terms of Use and Privacy Policy.  In addition, you agree to receive information regarding Quanterix products and services.  You will be able to unsubscribe at any time.

Follow Us!


Learn more about groundbreaking Simoa technology!

With much enthusiasm following the research coming out of AD/PD™2021, we are pleased to bring together leading industry experts to discuss neurological advancements related to the ultra-sensitive quantification of pTau181, pTau217, pTau231, and other neurological biomarkers. This panel discussion and live Q and A will cover the latest developments and opportunities to impact AD clinical trials and diagnostics.

The discussion will be led by Quanterix Chairman, Chief Executive Officer, and President, Kevin Hrusovsky and will feature Charlotte Teunissen, Ph.D., UMC Amsterdam, and Henrik Zetterberg. Ph.D., University of Gothenberg.